Back to results

CompletedPhase 2

Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer

NCT00216021

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Helen F. Graham Cancer Center

Newark, Delaware, United States

+10 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2004-03
Enrollment: 25 participants
Sponsor: Hoosier Cancer Research Network
Purpose: treatment

Locations (11)

Helen F. Graham Cancer CenterNewark, Delaware, United States
Medical & Surgical Specialists, LLCGalesburg, Illinois, United States
Elkhart ClinicElkhart, Indiana, United States
Oncology Hematology Associates of SW IndianaEvansville, Indiana, United States
Indiana University Cancer CenterIndianapolis, Indiana, United States
Quality Cancer Center (MCGOP)Indianapolis, Indiana, United States
Community Regional Cancer CenterIndianapolis, Indiana, United States
Medical Consultants, P.C.Muncie, Indiana, United States
Center for Cancer Care, Inc., P.C.New Albany, Indiana, United States
Northern Indiana Cancer Research ConsortiumSouth Bend, Indiana, United States
AP&S ClinicTerre Haute, Indiana, United States

Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer — TrialFind